Drug intelligence / Profile preview

68Ga-2K015

Lead developer
Novartis
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
Administration
Intravenous
01

Overview

68Ga-2K015 is a novel Nectin-4-targeting peptide radioligand developed by Zonsen PepLib Biotech. It consists of the novel peptide ligand 2K015, which was discovered and optimized using PepLib's AI-driven in silico peptide design and disulfide-rich peptide phage display platform, conjugated to DOTA and radiolabeled with Gallium-68 (68Ga). 68Ga-2K015 exhibits picomolar binding affinity to human Nectin-4, a tumor-associated cell surface antigen highly expressed in urothelial carcinoma and other solid tumors. In preclinical evaluations, 68Ga-2K015 demonstrated high tumor uptake and favorable biodistribution, with lower kidney uptake compared to the benchmark comparator 68Ga-BT8009. In a human investigator-initiated trial (IIT) involving patients with urothelial carcinoma, 68Ga-2K015 achieved clear tumor imaging with low liver and kidney uptake, highlighting its potential as a diagnostic PET imaging tracer for Nectin-4-positive malignancies.

Other names
gallium Ga 68 2K015gallium-68 2K015gallium68 2K015gallium 68 2K015
02

Identity

Drug type
Peptides
Originator
PepLib
Modality
PeptidesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesPositron Emitters
Synonyms and codes
2K015
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
urothelial carcinoma of urinary tractIn developmentActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Competitive landscape

Drugs on the same target
38
Drugs in the lead indication
346

Lead indication: urothelial carcinoma of urinary tract

Most advanced in the lead indication

  1. enfortumab vedotinApproved
  2. avelumabApproved
  3. nivolumabApproved
  4. pembrolizumabApproved
  5. measles virus vaccine live attenuatedApproved

Beyond the preview

Go deeper on 68Ga-2K015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-2K015.

Work on 68Ga-2K015? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call